King of Prussia, PA – According to filings with the U.S. Securities and Exchange Commission, Genomind is raising $21,725,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Koffler played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Genomind

Genomind is a mental health biotechnology and digital service company bringing innovative solutions to personalized mental healthcare and wellness through genetic testing. Genomind Professional PGx Express is an industry-leading prescription pharmacogenetic test that equips mental health professionals with tools they need to more quickly identify a personalized treatment plan for their patients. Genomind Mental Health Map is the first-ever genetic test available direct-to-consumer designed specifically for mental wellness. It provides powerful new insights and actions through reports in the 7 Core Genetic Mental Health Capabilities by analyzing genetic makeup across 35 genes, 38 genetic variants, 21 genetic mechanisms, and 59 mental health predispositions.

To learn more about Genomind, visit http://www.genomind.com/

Contact:
Michael Koffler, Chief Executive Officer
877-859-8658
michael.koffler@genomind.com
https://www.linkedin.com/in/michael-koffler-28a76824/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved